To the Editor, Mendelian type I interferonopathies are an increasingly recognized cause of treatment-refractory multisystem inflammation [1] . Here we report the beneficial effect of the JAK 1/2 inhibitor ruxolitinib in an infant with progressive neurological and lupus-like disease due to MDA5 gain-of-function.
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This female demonstrated delayed motor development from early infancy with lower limb hypertonia and dysarthria. Cranial MRI at age 29 months revealed a non-specific periventricular high signal T2 signal. Spinal cord imaging was normal. Her father had experienced a slowly progressive spastic paraparesis affecting his lower limbs, so that a diagnosis of hereditary spastic paraparesis was suggested.
At 3 years of age, she presented with a 2-week history of retching, reduced appetite, and weight loss. Cognition was age appropriate and vision and hearing were normal. However, regression became evident over the following 6 months, with evolution of her motor disorder, continued retching, irritability, and the onset of oculogyric crises. Repeat imaging demonstrated more diffuse cerebral white matter signal change, with the spinal cord again normal. She continued to deteriorate, and at age 3 years 8 months developed an acute flaccid monoparesis of the right upper limb. As previously described [2] , imaging revealed a longitudinally extensive transverse myelitis, significant cerebral atrophy, and increased white matter T2 high signal. Strongly positive serum and cerebrospinal fluid (CSF) aquaporin 4 antibody titers led to a diagnosis of neuromyelitis optica. Antinuclear antibodies (1:160), anti-neutrophil cytoplasmic antibodies, and antidouble-stranded DNA (82.6 IU/mL) antibodies were also detected. Given a raised CSF neopterin (1035, normal range 7-65 nmol/L) and upregulation of interferon-stimulated genes (ISGs) in peripheral blood, a provisional diagnosis of type I interferonopathy was subsequently confirmed by the finding of a pathogenic IFIH1 mutation (c.1483G.A; p.Gly495Arg).
Rheumatology assessment highlighted alopecia, palmar erythema, livedo, and arthritis. Elevated erythrocyte sedimentation rate, transaminases, urinary protein/creatinine ratio, and lupus anticoagulant indicated a lupus-like illness. A dramatic improvement of her monoparesis and social interaction was observed following steroid treatment, comprising oral prednisolone tapering over 6 weeks supplemented by 4 weekly Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10875-018-0563-2) contains supplementary material, which is available to authorized users. intravenous (IV) methylprednisolone. She was also treated with mycophenolate mofetil (MMF) and rituximab, with CD19 cells undetectable after 3 months. Clinical disease was subsequently controlled on maintenance oral prednisolone (1 mg/kg) and MMF. During this time, she could use a standing frame, her speech became clearer, cognition improved, and she made progress at school. However, she exhibited significant spastic dystonia, and any attempt to wean steroids below 0.4 mg/kg daily, or stop 3-4 weekly 30 mg/kg doses of IV methylprednisolone, was associated with a regression of speech and motor function, increased irritability, and reduced social interaction reported by her parents and observed in clinic. Growth was static, below the 0.4th centile for height and weight, despite optimized nutrition and nasogastric supplementation, and in the absence of identifiable endocrinological dysfunction. At age 5 years, she developed a psoriasiform rash in a perianal, truncal, and facial distribution. Zinc levels were normal and the rash was thought to be part of her lupus-like illness.
Considering her skin disease and continued steroid dependency, at age 7.5 years, MMF and IV methylprednisolone were stopped and treatment with ruxolitinib was initiated (2.5 mg bd increasing to 5 mg bd after 1 month). Soon after commencement of therapy, there was a complete resolution of her rash and her parents described a marked improvement in her general well-being, with increased attention at home and school. Prednisolone was weaned and then discontinued 20 months after starting ruxolitinib. Consistent with these observations, there was enhanced growth and a fall in the interferon score from 13.14 at the time of ruxolitinib initiation to 3.45 (normal < 2.44) after 2 years of treatment ( Fig. 1 and  Supplementary Fig. 3 ). Over the next 2 years, the dose was subsequently increased in 2.5-mg increments during two apparent disease flares to 10 mg bd, the first of which was associated with an increase in the interferon score. On both occasions, her rash returned, albeit in a much milder form than prior to ruxolitinib. Before the initiation of ruxolitinib, most intercurrent respiratory infections were accompanied by increased severity of the psoriasiform rash, together with lethargy and disinterest in social interactions. After starting ruxolitinib, her parents reported that she tolerated most intercurrent respiratory infections better.
Our patient had an MDA5 gain-of-function mutation resulting in interferon-mediated inflammation signaling through the type I interferon receptor and JAK 1, as evidenced by elevated ISGs in blood and the inflammatory marker neopterin in the CSF. Her phenotype was clearly responsive to immunosuppression. However, she demonstrated continued Fig. 1 Interferon scores (ISs) and weight before and during ruxolitinib therapy. The median fold change of 6 interferon-stimulated genes is compared to the median in 29 previously assessed healthy controls to create an IS, with an abnormal score being defined as greater than 2 SD above the mean of the control group (i.e., > 2.466 is considered abnormal; dotted line) [3] . Red dots indicate ISs taken while on ruxolitinib. Numbers in blue are Z scores for weight. The numbers associating with dotted lines are the doses of prednisolone (per kg/day). The numbers associating with solid lines are the doses of ruxolitinib (mg bd) disease despite treatment with steroids, MMF, and rituximab. In this context, JAK 1/2 inhibition was associated with remarkable clinical improvements, allowing the stopping of steroid therapy. These changes were accompanied by a slow but sustained reduction in interferon signaling in blood, as assessed by the expression of genes induced by interferon. Importantly, ruxolitinib was well tolerated. However, immunosuppression is a potential risk, and rebound cytokine storm has been described on withdrawal [4] .
There are no licensed therapies for type I interferonopathies, with previous experience highlighting their refractoriness to conventional immunosuppression. Ruxolitinib demonstrates a favorable therapeutic effect in patients with activating STING mutations [5, 6] , and more recently a single case was reported demonstrating an apparent improvement of neurological features in the context of MDA5 gain-of-function [7] . The data presented here further highlight the potential therapeutic efficacy of JAK 1/2 inhibition in disorders associated with enhanced interferon signaling.
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